Crunching the numbers for ANVS... Refresh in a moment for the full analysis.
Annovis Bio, Inc. (ANVS)
Healthcare
mixed
$1.59
Updated: 2026-04-12
52
TradeApes Score
hold
Financial Strength
45
Mixed
Operating Trend
50
Mixed
Valuation
50
Mixed
Capital Allocation
50
Mixed
Risk
80
Strong
Key Findings
+
Strong FCF growth — free cash flow up more than 20% year over year
−
Negative ROIC — business destroying value on invested capital
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.